Objective
A randomized, open-label trial was conducted comparing the early onset of relief in the treatment of patients with signs and symptoms of BPH with either tamsulosin or terazosin.
Design
In this trial, 1993 men were randomized to tamsulosin (0.4 mg/day) or terazosin (5 mg/day, following titration). The primary efficacy endpoint for this study was the total AUA Symptom Score after four days of treatment. Secondary endpoints included score changes on measures of BPH symptoms and other clinical assessment instruments at six time points through the end of the study period (Day 57).1,2
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
1. Narayan P, O'Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005;5:237-245.
2. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
